InflaRx to Present New INF904 Preclinical Data at 19th European Complement Meeting

InflaRx N.V., a biopharmaceutical company based in Jena, Germany, and listed on Nasdaq under the ticker IFRX, has announced its participation in the upcoming 2024 European Meeting on Complement in Human Diseases (EMCHD). This event will take place in Lübeck, Germany, from September 2 to September 6, 2024. InflaRx is set to present promising preclinical data on its novel oral C5aR inhibitor, INF904.

InflaRx's contributions to the conference include two poster presentations, a focused panel discussion on the C5a/C5aR axis, and a satellite symposium. The meeting aims to highlight recent advances in the complement field, promoting the translation of basic scientific discoveries into new therapeutic approaches for human diseases. InflaRx is also a corporate sponsor of the event, reflecting its dedication to developing treatments for complement-mediated conditions.

The first poster, titled "INF904, a novel oral C5a receptor 1 (C5aR1) antagonist, shows promising therapeutic effects in inflammatory disease models" (P19), is authored by Zhongli Xu, Rui Liu, Ophelia Chen, Bruce P. Burnett, Maria Habel, and Renfeng Guo. The second poster, "Preclinical pharmacological characterization of INF904, an oral small molecule antagonist to complement 5a receptor1 (C5aR1)" (P20), features the same team of authors. These posters will showcase the therapeutic effects and pharmacological profile of INF904.

Prof. Niels C. Riedemann, InflaRx's Chief Executive Officer and Founder, will speak about "Inhibition of the C5a/C5aR1 axis in inflammation" in a satellite symposium on Monday, September 2, from 3:00 to 3:30 pm CET. Additionally, he will participate in a panel discussion titled "Targeting C3 and/or C5 Pathways" on the same day from 4:00 to 5:00 pm CET. Another session, a lunch seminar on Tuesday, September 3, from 1:00 to 1:45 pm CET, will feature Prof. Riedemann alongside Dr. Renfeng Guo, Chief Scientific Officer and Founder, and Dr. Camilla Chong, Chief Medical Officer. They will discuss "Complement C5a/C5aR inhibition in human disease with best-in-class inhibitors."

INF904 is an orally administered, small molecule inhibitor targeting the C5a receptor, displaying significant anti-inflammatory effects in various preclinical models. Unlike other marketed C5aR inhibitors, INF904 has shown minimal inhibition of the cytochrome P450 3A4/5 (CYP3A4/5) enzymes, which are crucial for metabolizing a range of drugs and metabolites, including glucocorticoids. Data from the first human study indicate that INF904 is well tolerated and does not present safety concerns at single doses from 3 mg to 240 mg or multiple doses from 30 mg once daily to 90 mg twice daily over 14 days. Pharmacokinetic and pharmacodynamic analyses suggest that INF904 could be a best-in-class inhibitor, achieving over 90% blockade of C5a-induced neutrophil activation.

InflaRx N.V. operates through its subsidiaries InflaRx GmbH in Germany and InflaRx Pharmaceuticals Inc. in the USA. Established in 2007, InflaRx is at the forefront of anti-inflammatory therapeutics. The company utilizes proprietary anti-C5a and anti-C5aR technologies to develop highly specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a potent inflammatory mediator implicated in numerous inflammatory diseases.

InflaRx's lead product candidate, vilobelimab, is an intravenously administered, first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a. It has shown disease-modifying clinical activity and tolerability in multiple studies across various indications. Alongside vilobelimab, InflaRx is advancing INF904, its oral small molecule C5aR inhibitor.

With offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA, InflaRx is committed to developing new therapies to target inflammatory diseases.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!